Difference between revisions of "Gestational trophoblastic neoplasia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "?Regimen |limit=10000|format=sum}} regimens" to "?Regimen |limit=10000|format=sum}} regimens") |
(correction in dactinomycin frequency) |
||
| Line 29: | Line 29: | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | *[[Dactinomycin (Cosmegen)]] 1.25 mg/m<sup>2</sup> IV push | + | *[[Dactinomycin (Cosmegen)]] 1.25 mg/m<sup>2</sup> IV push once every 2 weeks |
'''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | '''Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"''' | ||
Revision as of 18:24, 12 April 2018
4 regimens on this page
6 variants on this page
|
Low-risk disease, all lines of therapy
Dactinomycin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Osborne et al. 2011 (GOG) | Phase III | Methotrexate | Seems to have superior CR rate |
Chemotherapy
- Dactinomycin (Cosmegen) 1.25 mg/m2 IV push once every 2 weeks
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed
Methotrexate monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Osborne et al. 2011 (GOG) | Phase III | Dactinomycin | Seems to have inferior CR rate |
Chemotherapy
- Methotrexate (MTX) 30 mg/m2 IM once per week
Treatment continued "until the βhCG assay had reached the institutional normal, or until either a rise or plateau in the βhCG level was observed"
References
- Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Epub 2011 Jan 24. link to original article link to PMC article contains verified protocol PubMed